Next Chapter Holdings logo

Next Chapter Holdings

North America, Illinois, United States, Highland Park

Description

Next Chapter Holdings (NCH), located in Highland Park, Illinois, is the family office which manages investments of the Pattis family.

Investor Profile

Next Chapter Holdings has made 2 investments, with 1 in the past 12 months and 0% as lead.

Stage Focus

  • Series A (50%)
  • Series E (50%)

Country Focus

  • United States (100%)

Industry Focus

  • Mobile
  • Mobile Apps
  • Software
  • Biopharma
  • Biotechnology
  • Pharmaceutical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Next Chapter Holdings frequently co-invest with?

UO
North America, Ohio, United States, Cleveland
Co-Investments: 1
Birchmere Ventures
North America, Pennsylvania, United States, Pittsburgh
Co-Investments: 1
Bay City Capital
North America, California, United States, San Francisco
Co-Investments: 1
Frontier Angels
North America, Montana, United States, Bozeman
Co-Investments: 1
JobsOhio
North America, Ohio, United States, Columbus
Co-Investments: 1
New Dominion Angels
North America, Virginia, United States, Warrenton
Co-Investments: 1
Alta Partners
North America, Mississippi, United States, Jackson
Co-Investments: 1
Jumpstart Ventures
North America, Illinois, United States, Chicago
Co-Investments: 1
North Coast Ventures
North America, Ohio, United States, Cleveland
Co-Investments: 1
VisionTech Partners
North America, Indiana, United States, Indianapolis
Co-Investments: 1

What are some of recent deals done by Next Chapter Holdings?

OnStation

Cleveland, Ohio, United States

OnStation builds an app that provides instant jobsite location, access to plans and design, and a team communication tool.

MobileMobile AppsSoftware
Series AJun 10, 2024
Amount Raised: $8,500,000
CymaBay Therapeutics

Hayward, California, United States

CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases.

BiopharmaBiotechnologyPharmaceutical
Series ENov 5, 2009
Amount Raised: $8,600,000